urapidil has been researched along with Hypertension, Pulmonary in 13 studies
Hypertension, Pulmonary: Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Urapidil can prevent hypoxic pulmonary hypertension." | 7.72 | [Preventive effects of urapidil on hypoxic pulmonary hypertension in rats]. ( Chen, XJ; Cheng, DY; Guan, J; Xia, XQ, 2004) |
| "Urapidil is a new vasodilator that acts by postsynaptic alpha 1-blockade while inhibiting the aortic pressure baroreceptor reflex and reducing central sympathetic tone." | 6.66 | Hemodynamic effects of urapidil in patients with pulmonary hypertension. A comparative study with hydralazine. ( Abrouk, F; Adnot, S; Brun-Buisson, C; Defouilloy, C; Lemaire, F; Piquet, J, 1987) |
| "Urapidil is known to be an alpha 1-adrenoceptor antagonist and an agonist of central 5HT1A-receptors, and should be considered as a vasodilator." | 5.29 | Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil. ( Adnot, S; Samoyeau, R; Weitzenblum, E, 1995) |
| "Urapidil can prevent hypoxic pulmonary hypertension." | 3.72 | [Preventive effects of urapidil on hypoxic pulmonary hypertension in rats]. ( Chen, XJ; Cheng, DY; Guan, J; Xia, XQ, 2004) |
| "Urapidil is a new vasodilator that acts by postsynaptic alpha 1-blockade while inhibiting the aortic pressure baroreceptor reflex and reducing central sympathetic tone." | 2.66 | Hemodynamic effects of urapidil in patients with pulmonary hypertension. A comparative study with hydralazine. ( Abrouk, F; Adnot, S; Brun-Buisson, C; Defouilloy, C; Lemaire, F; Piquet, J, 1987) |
| "Urapidil is known to be an alpha 1-adrenoceptor antagonist and an agonist of central 5HT1A-receptors, and should be considered as a vasodilator." | 1.29 | Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil. ( Adnot, S; Samoyeau, R; Weitzenblum, E, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (38.46) | 18.7374 |
| 1990's | 7 (53.85) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Xia, XQ | 1 |
| Cheng, DY | 1 |
| Guan, J | 1 |
| Chen, XJ | 1 |
| Späh, F | 2 |
| Kottman, R | 1 |
| Schmidt, U | 2 |
| Adnot, S | 4 |
| Samoyeau, R | 1 |
| Weitzenblum, E | 1 |
| Galinier, M | 1 |
| Rougé, P | 1 |
| Fourcade, J | 1 |
| Senard, JM | 1 |
| Albenque, JP | 1 |
| Balanescu, S | 1 |
| Doazan, JP | 1 |
| Montastruc, JL | 1 |
| Bounhoure, JP | 1 |
| Montastruc, P | 1 |
| Lewczuk, J | 1 |
| Wrabec, K | 1 |
| Kottmann, R | 1 |
| Grosser, KD | 1 |
| Thieme, G | 1 |
| M'Buyamba-Kabangu, JR | 1 |
| Bielen, E | 2 |
| Staessen, J | 2 |
| Fagard, R | 2 |
| Lijnen, P | 2 |
| Van Hoof, R | 2 |
| Amery, A | 2 |
| Andrivet, P | 1 |
| Piquet, J | 2 |
| Brun-Buisson, C | 2 |
| Rauss, A | 1 |
| Bignon, J | 1 |
| Lemaire, F | 3 |
| Defouilloy, C | 2 |
| Abrouk, F | 2 |
| Kouzan, S | 1 |
| Rubin, LJ | 1 |
2 reviews available for urapidil and Hypertension, Pulmonary
| Article | Year |
|---|---|
[Value of vasodilator agents in the treatment of diseases with pulmonary hypertension caused by chronic obstructive lung diseases].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Blood Pressure; Calcium Channel B | 1991 |
Urapidil-induced hemodynamic changes in humans.
Topics: Acute Disease; Antihypertensive Agents; Heart Failure; Hemodynamics; Humans; Hypertension; Hypertens | 1989 |
3 trials available for urapidil and Hypertension, Pulmonary
| Article | Year |
|---|---|
Effects of single intravenous administration of urapidil and diltiazem in patients with nonfixed pulmonary hypertension secondary to chronic obstructive lung disease.
Topics: Adrenergic alpha-Antagonists; Adult; Aged; Antihypertensive Agents; Blood Pressure; Diltiazem; Femal | 1994 |
The effects of urapidil therapy on hemodynamics and gas exchange in exercising patients with chronic obstructive pulmonary disease and pulmonary hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Carbon Dioxide; Clinical Trials as Topic; Forced Expi | 1988 |
Hemodynamic effects of urapidil in patients with pulmonary hypertension. A comparative study with hydralazine.
Topics: Aged; Blood Pressure; Cardiac Output; Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmo | 1987 |
8 other studies available for urapidil and Hypertension, Pulmonary
| Article | Year |
|---|---|
[Preventive effects of urapidil on hypoxic pulmonary hypertension in rats].
Topics: Adrenergic alpha-Antagonists; Animals; Arterioles; Heart Ventricles; Hypertension, Pulmonary; Hypoxi | 2004 |
Treatment of pulmonary hypertension in patients with chronic obstructive pulmonary disease: position of vasodilators with special focus on urapidil.
Topics: Antihypertensive Agents; Blood Pressure; Humans; Hypertension, Pulmonary; Lung Diseases, Obstructive | 1995 |
Lack of haemodynamic effects of nitric oxide on post-capillary pulmonary hypertension induced by acute sino-aortic denervation.
Topics: Adrenergic beta-Antagonists; Animals; Denervation; Dogs; Enzyme Inhibitors; Hemodynamics; Hypertensi | 1997 |
[Therapy of hypertensive crises. Profile of intravenous Ebrantil].
Topics: Antihypertensive Agents; Humans; Hypertension; Hypertension, Pulmonary; Injections, Intravenous; Int | 1994 |
Effects of urapidil in patients with mild pulmonary vascular hypertension.
Topics: Aged; Antihypertensive Agents; Female; Hemodynamics; Humans; Hypertension, Pulmonary; Injections, In | 1990 |
[Hemodynamic effects of urapidil in men].
Topics: Antihypertensive Agents; Heart Failure; Hemodynamics; Humans; Hypertension; Hypertension, Pulmonary; | 1990 |
Haemodynamic effects of urapidil compared to hydralazine in pulmonary hypertension.
Topics: Female; Hemodynamics; Humans; Hydralazine; Hypertension, Pulmonary; Male; Oxygen; Piperazines | 1986 |
Vasodilators and pulmonary hypertension: where do we go from here?
Topics: Blood Pressure; Humans; Hydralazine; Hypertension, Pulmonary; Piperazines; Pulmonary Circulation; Va | 1987 |